Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Non Operating Income (2016 - 2025)

Aptevo Therapeutics' Non Operating Income history spans 11 years, with the latest figure at $61000.0 for Q3 2025.

  • For Q3 2025, Non Operating Income fell 45.54% year-over-year to $61000.0; the TTM value through Sep 2025 reached $225000.0, down 61.86%, while the annual FY2024 figure was $472000.0, 18.34% down from the prior year.
  • Non Operating Income for Q3 2025 was $61000.0 at Aptevo Therapeutics, up from $22000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $230000.0 in Q2 2023 and bottomed at -$2.6 million in Q4 2021.
  • The 5-year median for Non Operating Income is $22000.0 (2025), against an average of -$570000.0.
  • The largest annual shift saw Non Operating Income plummeted 58650.0% in 2021 before it skyrocketed 1008.0% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$2.6 million in 2021, then soared by 100.82% to $21000.0 in 2022, then surged by 795.24% to $188000.0 in 2023, then tumbled by 62.77% to $70000.0 in 2024, then fell by 12.86% to $61000.0 in 2025.
  • Per Business Quant, the three most recent readings for APVO's Non Operating Income are $61000.0 (Q3 2025), $22000.0 (Q2 2025), and $72000.0 (Q1 2025).